证券代码：300100 证券简称：双林股份 双林股份有限公司 投资者关系活动记录表 编号：2026-01 | | √特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □电话会议 | | | √其他：双林十万套丝杠产线、新一代磨床投产发布会 华鑫证券、国联基金、国泰基金、海通怡投资管理有限公司、上海彰天 | | | 投资管理有限公司、中泰国际、光大证券、民生证券、国盛证券、开源 证券、天风证券、长江证券、中金公司、中邮证券、上海韦豪创芯投资 | | | 管理有限公司、工业母机产业投资基金、广汽资本、国器元禾、金景资 | | | 本、宁波通商基金、首钢基金、浙江省创业投资集团有限公司、浙江省 | | 参与单位名称 | 发展资产、浙江省国有资本运营有限公司、工银瑞信基金、兴业证券香 | | | 港、国泰海通资管、上海九祥资产、银河证券、永赢基金、华源证券、 | | | 大成基金、国金基金、惠升基金、浙江国有资本、清研资本、春雷基金、 | | | 海富通基金、华安基金、光大保德信、路博迈、高 ...

作者丨欧雪 编辑丨袁斯来 硬氪获悉，专注于热模锻工业母机的武汉新威奇科技有限公司（下称"新威奇"）已于近期完成数千万元首轮融资。我们总结了本轮融资信息和该公司几大 亮点： 融资金额与资金用途 融资轮次：首轮融资 融资金额：数千万元 投资机构：国家工业母机基金 资金用途：主要用于超大型伺服直驱电动螺旋压力机的重型生产能力建设，并支持研发投入。旨在突破现有产能瓶颈，为交付万吨级以上设备奠定基础 公司基本信息 成立时间：1993年（前身为华中科技大学校办企业，2010年实现产业化运营） 总部地点：湖北省武汉市 核心产品：以伺服直驱式数控电动螺旋压力机为核心，配套数控伺服液压机等全系列精密模锻成形设备，并提供"设备+工艺+自动化+数字化+智能化"整 体解决方案。 技术亮点：掌握自主研发的超大型永磁同步电机直驱技术，实现"零传动"，在打击精度、能效比和设备稳定性方面达到国际领先水平，已交付6300吨级国 产首台套、全球最大吨位的伺服直驱数控电动螺旋压力机。 新威奇模锻整体解决方案（图源/企业） 产品应用：产品批量应用于航空发动机叶片、燃气轮机叶片、汽车转向节、特高压输电线路器材等高端锻件制造，服务中航工业、三环锻造等国 ...

中经记者 李哲 惠州报道 12月22日，亿纬锂能（300014.SZ）"亿纬钠能总部和金源机器人AI中心"项目正式动工。 亿纬锂能方面表示，项目建成后将成为国内领先的钠电产业化以及AI和机器人创新应用融合基地。其 中，2GWh钠离子电池产能将有效填补市场供需缺口，推动储能、AIDC等场景规模化应用。 "这是一个新的时代，AI的时代，不是制造的时代。今年年底我们的销售额能够超过600亿元，2026年预 计将达到800亿元，我们的奋斗目标是1000亿元。"亿纬锂能董事长刘金成表示，面对AI时代全面到来的 产业变革，亿纬锂能顺势布局，一方面借助AI全面推动锂电池制造智能化升级，全力实现"机器人为机 器人造电池"的梦想；另一方面通过建设超大规模锂电池生产工厂，反向赋能AI技术产品迭代，二者相 辅相成。 钠电项目预计2027年试生产 根据亿纬锂能方面披露，在钠电板块，项目总投资约10亿元，规划总建筑面积约9万平方米，规划年产 能2GWh。 亿纬锂能中央研究院院长赵瑞瑞介绍，该项目生产的钠离子电池具备宽温域、高倍率、长寿命、高安全 性等优势，能提供安全绿色的电力供应，快速响应AIDC负荷变化，为场景运行提供稳定高效的储能 ...

Investment Rating - The report maintains a rating of "Buy" for the company, with a target price of 25.27 CNY, corresponding to a PE ratio of 24.8 for 2025 [3][9]. Core Insights - The company's net profit attributable to shareholders decreased by 24.3% in the first three quarters of 2025, while new contracts signed increased by 1.6%. The company is continuously enhancing its intelligent manufacturing capabilities, which has led to a reduction in production costs through the deployment of nearly 2,500 lightweight welding robots and rail-type robotic welding stations [2][4]. - The report indicates a downward revision in the earnings per share (EPS) forecast for 2025-2027, with expected EPS of 1.02, 1.18, and 1.32 CNY, reflecting changes of -9.2%, 16.0%, and 12.2% respectively [3][4]. Financial Performance Summary - For the first three quarters of 2025, the company reported revenue of 15.92 billion CNY, a slight increase of 0.2% year-on-year. The net profit attributable to shareholders was 500 million CNY, down 24.3% compared to the previous year [4]. - The gross profit margin increased by 0.2 percentage points to 10.4%, while the net profit margin decreased by 1.0 percentage points to 3.1% [4]. - The company achieved a net cash inflow from operating activities of 380 million CNY in the first three quarters of 2025, compared to 330 million CNY in the same period of 2024 [5]. Contract and Production Insights - New contracts signed in the first three quarters of 2025 totaled 22.27 billion CNY, reflecting a 1.6% increase from the same period in 2024. The breakdown includes 22.24 billion CNY in material orders and 30 million CNY in engineering orders [5][19]. - The production volume of steel structure products reached approximately 3.61 million tons, an increase of 11.1% year-on-year [5]. Intelligent Manufacturing Initiatives - The company has significantly invested in intelligent manufacturing, with nearly 2,500 lightweight welding robots and rail-type robotic welding stations now in large-scale operation. This initiative is expected to greatly enhance product quality and reduce production costs in the long term [6].

登高望远布局未来。开继重工一期项目计划年产量6万吨，预计实现销售额3亿元。下一步，企业将视市 场情况推进二期、三期项目建设，逐步实现年产35万吨钢结构的远景目标。为推动传统产业向提质、降 本、增效、绿色、安全方向发展，企业已投资800万元与中国移动（600941）合作打造5G工厂，借助5G 技术实现生产单元广泛连接、IT-OT深度融合、数据要素充分利用，并在研发设计、生产制造、质量检 测、仓储物流、运营管理等环节落地5G创新应用。目前该项目已成功入库，预计2026年将获得工信部 门批复。 展望未来，开继重工将继续依托过硬品质，全面切入长三角地区的建筑、机械制造、能源基建等核心市 场，并凭借口碑积累与品质认证，逐步拓展全国业务版图。通过对标国际标准、提升综合竞争力，企业 将积极参与全球产业链分工，为国内外重大工程与高端制造提供优质金属结构解决方案，致力成为行业 发展的新标杆。 11月27日上午9点，盐城市射阳县海河镇开继重工（江苏）有限公司生产车间内机器轰鸣、焊花飞溅。 外场成品库区，3辆大型货车有序排列，2辆叉车穿梭往返，将刚刚下线的金属结构件产品运装上车…… 这家今年7月才投产的企业，凭借领先的工艺技能与过 ...

Core Viewpoint - The company is expanding its production capacity by investing in a new manufacturing base for functional oral care products in Jiangsu Province, aiming to enhance operational efficiency and product quality while integrating smart manufacturing technologies [2][4]. Group 1: Project Details - The total investment for the expansion project is estimated at 68.85 million yuan, with construction costs accounting for 45.39 million yuan and equipment and software purchases at 23.46 million yuan [3]. - The project will involve the construction of a six-story factory building with a total area of 22,749 square meters, including a toothpaste production workshop of 18,199 square meters and a hotel slipper production workshop of 4,550 square meters [2][3]. - The construction period is expected to last 14 months, with equipment purchases and capacity integration implemented in phases based on market conditions [3]. Group 2: Business Overview - The company operates in two main sectors: daily chemicals and pharmaceuticals, focusing on the "big consumption, big health" industry [3]. - The daily chemicals segment includes the development, production, and sales of oral care products, personal care items, and hotel supplies, with key brands such as Two-Mouth Needle and Mu Lan Ze [3]. - The pharmaceutical segment produces and sells various medications, including capsules and raw materials, managed by Yikang Pharmaceutical [3]. Group 3: Financial Performance - The Jiangsu company has shown stable operational performance, with projected revenues of 761 million yuan for 2024 and 437 million yuan for the first half of 2025, alongside net profits of 11.95 million yuan and 6.44 million yuan, respectively [3]. - The company has identified a growing need for capacity support and equipment efficiency improvements due to increasing market orders, which has impacted order fulfillment and limited sustainable growth [3][4]. Group 4: Strategic Implications - The project aims to overcome existing capacity bottlenecks by introducing advanced equipment and optimizing production processes, thereby enhancing automation and production efficiency [4]. - The establishment of a hotel slipper production line will reduce reliance on external suppliers and improve product offerings, thereby strengthening market share [4]. - The new facility is expected to provide better conditions for research and innovation, facilitating the iterative upgrade of herbal functional products to meet diverse market demands [4].

Core Points - The company has completed the fundraising project for digital system upgrades and production line intelligent transformation, and all raised funds have been fully utilized [2][7] - The company has decided to terminate the special fundraising account related to this project as it is no longer in use [8] Fundraising Project Overview - The fundraising project involved a non-public issuance of 24,392,247 shares at a price of 60.88 yuan per share, raising a total of 1,485 million yuan, with a net amount of 1,461.32 million yuan after deducting issuance costs [2][3] - The funds were managed under a special account system to ensure proper usage and compliance with relevant regulations [3][4] Fund Usage and Management - The company has adhered to the established management methods for the use of raised funds, ensuring that funds are used specifically for the intended project [3][4] - The project has undergone a delay in its construction period, which was extended to December 2023 due to macroeconomic conditions and operational considerations [5][6] Project Completion and Account Closure - The digital system upgrade and production line intelligent transformation project has been completed, enhancing the company's digital management and manufacturing efficiency [7] - The special fundraising account for this project has a balance of 0 yuan, leading to its closure and the termination of the corresponding three-party supervision agreement [8]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Views - The company reported a record high revenue in Q3, with total revenue for the first three quarters reaching 6.44 billion yuan, a year-on-year increase of 1.5%. However, the net profit attributable to shareholders was 1.02 billion yuan, a decrease of 41.2% year-on-year [2][6]. - The Q3 revenue alone was 2.32 billion yuan, reflecting a year-on-year increase of 3.9% and a quarter-on-quarter increase of 12.4%. The net profit for Q3 was 340 million yuan, down 47.0% year-on-year but up 10.6% quarter-on-quarter [2][6]. - The company is a leading domestic tire manufacturer with global leadership in intelligent manufacturing. The gradual release of domestic and overseas production capacity, combined with tariff advantages and high-end products backed by aviation tire technology, is expected to help the company establish a strong brand advantage and drive continuous growth in performance and brand [12]. Summary by Sections Financial Performance - For the first three quarters, the overall gross margin was 24.0%, down 11.4 percentage points year-on-year, and the net profit margin was 15.8%, also down 11.4 percentage points year-on-year. This decline is attributed to rising raw material prices and fluctuations in overseas trade tariffs [12]. - The Q3 gross margin was 23.0%, down 16.3% year-on-year and 3.4% quarter-on-quarter, primarily due to raw material price fluctuations and product mix adjustments [12]. Project Developments - The Morocco project is expected to continue ramping up production in Q4. The first phase of the project began operations on September 30, 2024, with a total annual production capacity of 12 million high-performance passenger car tires [12]. - The company is also expanding its international production capacity, with the second phase of its Thailand factory and the Morocco project being significant steps in its global development strategy [12]. Future Outlook - The company is expected to achieve net profits of 1.43 billion yuan, 2.13 billion yuan, and 2.51 billion yuan for the years 2025 to 2027, respectively [12].

Core Viewpoint - Xiling Power (300733) announced plans to acquire 100% equity of Weipai Automotive Electronics (Shanghai) Co., Ltd. through cash payment, which will make Weipai a wholly-owned subsidiary after the transaction is completed [1] Summary by Relevant Sections - **Transaction Details** - The transaction price includes a base payment, adjustments for net operating capital, cash and cash equivalents, and other current assets and liabilities [1] - The acquisition does not constitute a related party transaction or a major asset restructuring as defined by the regulations [1] - **Strategic Implications** - Weipai Automotive has industry-leading experience in fully automated digital intelligent production lines and precision manufacturing processes for turbochargers [1] - The integration of Weipai's advanced production line experience is expected to enhance Xiling Power's intelligent manufacturing capabilities [1]

Core Insights - Xianle Health reported a steady growth in revenue and net profit for the first three quarters of 2025, with revenue reaching 3.291 billion yuan, a year-on-year increase of 7.96%, and net profit of 260 million yuan, up 8.53% [1] - The company’s third-quarter performance showed significant growth, with revenue of 1.250 billion yuan, an 18.11% increase year-on-year, and net profit of 99 million yuan, up 16.20% [1] - The growth is attributed to the adaptation to new consumer trends, international market expansion, and innovation-driven strategies [1] Revenue and Market Performance - In Q3 2025, Xianle Health's revenue and order volume in China increased by over 20% and 25% year-on-year, respectively, with new consumer clients accounting for more than half of the company's revenue in the region [1] - The company’s revenue from MCN and private domain clients grew by over 60% year-on-year, becoming the main growth engine in China [1] - Mainstream product categories and dosage forms saw revenue growth exceeding 60% and 50%, respectively [1] Product Innovation and International Expansion - Xianle Health enhanced its competitive edge in high-value sectors through core dosage technology and micro-innovation, launching the XtraGummy and NuPalette gummy series [2] - The company achieved over 20% year-on-year growth in its Americas export business, maintaining gross margins similar to the previous year, while European revenue increased by over 35% year-on-year in Q3 [2] - The company is expanding its presence in the Asia-Pacific and emerging markets, with plans for a new production facility in Thailand expected to produce 2.4 billion nutritional gummies annually by 2027 [2] R&D and Manufacturing Innovations - Xianle Health established a "Joint Innovation Fund" with the Chinese Institute of Food Science and Technology, focusing on delivery efficiency, nutritional health, and aging intervention [3] - The company’s smart logistics center in Shantou was launched in Q3, tripling storage capacity and improving inbound efficiency by approximately 70% [3] - The ongoing development of "dark factories" aims to create a standardized and replicable intelligent manufacturing system, enhancing supply chain collaboration and cost reduction [3]